Diarrhea News and Research

Latest Diarrhea News and Research

Actavis reports positive results from ceftazidime-avibactam Phase III studies in cIAI patients

Actavis plc today confirmed positive topline results from RECLAIM-1 and -2, pivotal Phase III studies evaluating the potential for the investigational antibiotic, ceftazidime-avibactam as a treatment for adult hospitalized patients with complicated intra-abdominal infections.

19 Aug 2014

Presence of Listeria monocytogenes in foods may cause abortions, meningitis

The results of the research conducted in the ICAS Culiacán reveal that at least 10 percent of the fresh cheese, sausages and meats sold in markets and on the street may be contaminated.

19 Aug 2014

Cases of Ebola virus in West Africa continue to rise

Since the Ebola virus outbreak was first reported in March there have been nearly 2,000 cases and over 1,000 deaths in Guinea, Liberia, Nigeria, and Sierra Leone. This makes it the most serious Ebola epidemic to date.

15 Aug 2014

Studies detect integrons that cause resistance to various antibiotics

In Mexico the sale of antibiotics for human consumption is controlled to prevent misuse, although in the veterinary sector failure in the implementation of the Official Mexican Standard NOM-064-ZOO-2000, "Guidelines for veterinarian products prescription", has prompted common bacteria such as Escherichia coli and Salmonella spp to become resistant to regular drugs such as streptomycin, trimethoprim, ampicillin, gentamicin, and tetracycline as a result of excess drug use.

12 Aug 2014

Inovio Pharmaceuticals reports increased revenue in second quarter 2014

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended June 30, 2014. Total revenue was $3.8 million and $6.2 million for the three and six months ended June 30, 2014, compared to $786,000 and $2.2 million for the same periods in 2013.

11 Aug 2014

Treating Americans with untested Ebola drug raises concerns

Using the experimental drug before it is tested in clinical trials will make it difficult to determine whether it is actually safe and effective, say scientists. Meanwhile, African officials say they have been inundated with requests from dying patients and their relatives for the same treatment.

7 Aug 2014

First Edition: August 6, 2014

Today's headlines include reports about the Gallup-Healthways Well-Being Index that details how politics play a role in the nation's health care gap between red and blue states.

6 Aug 2014

Phase 3 ASPIRE clinical trial meets primary endpoint of progression-free survival

Amgen and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that a planned interim analysis demonstrated that the Phase 3 clinical trial ASPIRE (CArfilzomib, Lenalidomide, and DexamethaSone versus Lenalidomide and Dexamethasone for the treatment of PatIents with Relapsed Multiple MyEloma) met its primary endpoint of progression-free survival (PFS).

4 Aug 2014

New molecular test kit predicts survival outcomes in kidney cancer patients

Researchers and doctors at the Institute of Bioengineering and Nanotechnology (IBN), Singapore General Hospital (SGH) and National Cancer Centre Singapore (NCCS) have co-developed the first molecular test kit that can predict treatment and survival outcomes in kidney cancer patients. This breakthrough was recently reported in European Urology, the world's top urology journal.

4 Aug 2014

GSK announces availability of once-weekly Tanzeum in pharmacies throughout the U.S.

GSK today announced that once-weekly Tanzeum (albiglutide), a prescription injectable treatment for type 2 diabetes in adults, as an adjunct to diet and exercise, is now available in pharmacies throughout the U.S.

29 Jul 2014

FDA approves use of Imbruvica to treat patients with chronic lymphocytic leukemia

The U.S. Food and Drug Administration today expanded the approved use of Imbruvica (ibrutinib) to treat patients with chronic lymphocytic leukemia (CLL) who carry a deletion in chromosome 17 (17p deletion), which is associated with poor responses to standard treatment for CLL. Imbruvica received a breakthrough therapy designation for this use.

29 Jul 2014

Researchers identify porcine enterovirus G using next-generation sequencing

He calls himself the bug hunter, but the target of his work consists of viruses that can only be found and identified with special methods and instruments.

29 Jul 2014

Norovirus vaccines: an interview with Dr Benjamin Lopman, Centers for Disease Control and Prevention, USA

Noroviruses are a group of viruses. They're the leading cause of gastroenteritis, which causes diarrhea and vomiting. They affect the whole age range from young children to the elderly, and, in the US, they cause about 20 million cases annually.

28 Jul 2014

Researchers examine effects of bacteria in fighting against obesity

A probiotic that prevents obesity could be on the horizon. Bacteria that produce a therapeutic compound in the gut inhibit weight gain, insulin resistance and other adverse effects of a high-fat diet in mice, Vanderbilt University investigators have discovered.

26 Jul 2014

EMA recommends full marketing approval for IMBRUVICA in the European Union

Pharmacyclics, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion recommending the granting of full marketing approval for IMBRUVICA (ibrutinib) in the European Union.

25 Jul 2014

Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary, today announced that an investigational Phase 3 trial of NEXAVAR (sorafenib) tablets in patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival (PFS).

25 Jul 2014

Zydelig gets FDA approval for treatment of patients with three types of blood cancers

The U.S. Food and Drug Administration today approved Zydelig (idelalisib) to treat patients with three types of blood cancers.

24 Jul 2014

FDA approves Ruconest for treatment of acute attacks in adolescent patients with HAE

The U.S. Food and Drug Administration yesterday approved Ruconest, the first recombinant C1-Esterase Inhibitor product for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema (HAE).

18 Jul 2014

FDA designated Astellas’ isavuconazole as QIDP for treatment of invasive candidiasis

Astellas today announced that the U.S. Food and Drug Administration (FDA) designated isavuconazole as a Qualified Infectious Disease Product (QIDP) for the treatment of invasive candidiasis, a life-threatening, invasive fungal infection.

17 Jul 2014

Medac Pharma's Rasuvo injection gets FDA approval for RA, pJIA and psoriasis

Medac Pharma, Inc., a privately held pharmaceutical company focused on the development of new molecules and improving the effectiveness of existing medicines, announced that the U.S. Food and Drug Administration has approved Rasuvo, a subcutaneous injectable methotrexate (MTX) therapy delivered in an auto-injector for rheumatoid arthritis (RA), polyarticular-course juvenile idiopathic arthritis (pJIA) and psoriasis.

14 Jul 2014

Diarrhea News and Research

Latest Diarrhea News and Research

Actavis reports positive results from ceftazidime-avibactam Phase III studies in cIAI patients

Presence of Listeria monocytogenes in foods may cause abortions, meningitis

Cases of Ebola virus in West Africa continue to rise

Studies detect integrons that cause resistance to various antibiotics

Inovio Pharmaceuticals reports increased revenue in second quarter 2014

Treating Americans with untested Ebola drug raises concerns

First Edition: August 6, 2014

Phase 3 ASPIRE clinical trial meets primary endpoint of progression-free survival

New molecular test kit predicts survival outcomes in kidney cancer patients

GSK announces availability of once-weekly Tanzeum in pharmacies throughout the U.S.

FDA approves use of Imbruvica to treat patients with chronic lymphocytic leukemia

Researchers identify porcine enterovirus G using next-generation sequencing

Norovirus vaccines: an interview with Dr Benjamin Lopman, Centers for Disease Control and Prevention, USA

Researchers examine effects of bacteria in fighting against obesity

EMA recommends full marketing approval for IMBRUVICA in the European Union

Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Zydelig gets FDA approval for treatment of patients with three types of blood cancers

FDA approves Ruconest for treatment of acute attacks in adolescent patients with HAE

FDA designated Astellas’ isavuconazole as QIDP for treatment of invasive candidiasis

Medac Pharma's Rasuvo injection gets FDA approval for RA, pJIA and psoriasis

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Diarrhea News and Research

Latest Diarrhea News and Research

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Newsletters you may be interested in